243 related articles for article (PubMed ID: 33870746)
1. Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry.
Scholle MD; Liu C; Deval J; Gurard-Levin ZA
SLAS Discov; 2021 Jul; 26(6):766-774. PubMed ID: 33870746
[TBL] [Abstract][Full Text] [Related]
2. Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry.
Pearson LA; Green CJ; Lin D; Petit AP; Gray DW; Cowling VH; Fordyce EAF
SLAS Discov; 2021 Jul; 26(6):749-756. PubMed ID: 33724070
[TBL] [Abstract][Full Text] [Related]
3. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase.
Basu S; Mak T; Ulferts R; Wu M; Deegan T; Fujisawa R; Tan KW; Lim CT; Basier C; Canal B; Curran JF; Drury LS; McClure AW; Roberts EL; Weissmann F; Zeisner TU; Beale R; Cowling VH; Howell M; Labib K; Diffley JFX
Biochem J; 2021 Jul; 478(13):2481-2497. PubMed ID: 34198328
[TBL] [Abstract][Full Text] [Related]
4. A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex.
Khalili Yazdi A; Li F; Devkota K; Perveen S; Ghiabi P; Hajian T; Bolotokova A; Vedadi M
SLAS Discov; 2021 Jul; 26(6):757-765. PubMed ID: 33874769
[TBL] [Abstract][Full Text] [Related]
5. The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2.
Ogando NS; Zevenhoven-Dobbe JC; van der Meer Y; Bredenbeek PJ; Posthuma CC; Snijder EJ
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938769
[TBL] [Abstract][Full Text] [Related]
6. Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors.
Riccio AA; Sullivan ED; Copeland WC
J Biol Chem; 2022 Jan; 298(1):101518. PubMed ID: 34942146
[TBL] [Abstract][Full Text] [Related]
7. New targets for drug design: importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2.
Saramago M; Bárria C; Costa VG; Souza CS; Viegas SC; Domingues S; Lousa D; Soares CM; Arraiano CM; Matos RG
FEBS J; 2021 Sep; 288(17):5130-5147. PubMed ID: 33705595
[TBL] [Abstract][Full Text] [Related]
8. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease.
Canal B; McClure AW; Curran JF; Wu M; Ulferts R; Weissmann F; Zeng J; Bertolin AP; Milligan JC; Basu S; Drury LS; Deegan TD; Fujisawa R; Roberts EL; Basier C; Labib K; Beale R; Howell M; Diffley JFX
Biochem J; 2021 Jul; 478(13):2445-2464. PubMed ID: 34198326
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification.
Baddock HT; Brolih S; Yosaatmadja Y; Ratnaweera M; Bielinski M; Swift LP; Cruz-Migoni A; Fan H; Keown JR; Walker AP; Morris GM; Grimes JM; Fodor E; Schofield CJ; Gileadi O; McHugh PJ
Nucleic Acids Res; 2022 Feb; 50(3):1484-1500. PubMed ID: 35037045
[TBL] [Abstract][Full Text] [Related]
10. Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.
Kasprzyk R; Spiewla TJ; Smietanski M; Golojuch S; Vangeel L; De Jonghe S; Jochmans D; Neyts J; Kowalska J; Jemielity J
Antiviral Res; 2021 Sep; 193():105142. PubMed ID: 34303749
[TBL] [Abstract][Full Text] [Related]
11. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.
Narayanan N; Nair DT
Int J Biol Macromol; 2021 Jan; 168():272-278. PubMed ID: 33309661
[TBL] [Abstract][Full Text] [Related]
12. A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19.
Perveen S; Khalili Yazdi A; Devkota K; Li F; Ghiabi P; Hajian T; Loppnau P; Bolotokova A; Vedadi M
SLAS Discov; 2021 Jun; 26(5):620-627. PubMed ID: 33423577
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target.
Tahir M
J Med Virol; 2021 Jul; 93(7):4258-4264. PubMed ID: 33837972
[TBL] [Abstract][Full Text] [Related]
14. Development of a Novel Label-Free and High-Throughput Arginase-1 Assay Using Self-Assembled Monolayer Desorption Ionization Mass Spectrometry.
Scholle MD; Gurard-Levin ZA
SLAS Discov; 2021 Jul; 26(6):775-782. PubMed ID: 33754845
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase.
Ahmed-Belkacem R; Sutto-Ortiz P; Guiraud M; Canard B; Vasseur JJ; Decroly E; Debart F
Eur J Med Chem; 2020 Sep; 201():112557. PubMed ID: 32563813
[TBL] [Abstract][Full Text] [Related]
17. The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target.
Rona G; Zeke A; Miwatani-Minter B; de Vries M; Kaur R; Schinlever A; Garcia SF; Goldberg HV; Wang H; Hinds TR; Bailly F; Zheng N; Cotelle P; Desmaële D; Landau NR; Dittmann M; Pagano M
Cell Death Differ; 2022 Feb; 29(2):285-292. PubMed ID: 34862481
[TBL] [Abstract][Full Text] [Related]
18. Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors.
Devkota K; Schapira M; Perveen S; Khalili Yazdi A; Li F; Chau I; Ghiabi P; Hajian T; Loppnau P; Bolotokova A; Satchell KJF; Wang K; Li D; Liu J; Smil D; Luo M; Jin J; Fish PV; Brown PJ; Vedadi M
SLAS Discov; 2021 Oct; 26(9):1200-1211. PubMed ID: 34192965
[TBL] [Abstract][Full Text] [Related]
19. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
[TBL] [Abstract][Full Text] [Related]
20. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture.
Wang X; Sacramento CQ; Jockusch S; Chaves OA; Tao C; Fintelman-Rodrigues N; Chien M; Temerozo JR; Li X; Kumar S; Xie W; Patel DJ; Meyer C; Garzia A; Tuschl T; Bozza PT; Russo JJ; Souza TML; Ju J
Commun Biol; 2022 Feb; 5(1):154. PubMed ID: 35194144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
